AXNX News and Press, Axonics Modulation Technologies Inc. From 03/05/19

AXNX - Axonics Modulation Technologies (AXNX) CEO Ray Cohen on Q4 2018 Results - Earnings Call Transcript

Axonics Modulation Technologies (AXNX) Q4 2018 Earnings Conference Call March 05, 2019 04:30 PM ET Company Participants Matt Clawson - W2O Group, Investor Relations Ray Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Karen Noblett - Chief Me...

AXNX - Axonics Modulation Technologies misses by $0.14, beats on revenue

Axonics Modulation Technologies (NASDAQ: AXNX ): Q4 GAAP EPS of -$0.50 misses by $0.14 . More news on: Axonics Modulation Technologies, Earnings news and commentary, Healthcare stocks news, Read more ...

AXNX - Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , reported today financi...

AXNX - Axonics® Appoints Michael H. Carrel to its Board of Directors

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced that Mi...

AXNX - Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced the sub...

AXNX - Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , announced today that i...

AXNX - Axonics up 9% on positive neuromodulation device data

Thinly traded Axonics Modulation Technologies ( AXNX +9.2% ) is up on modestly higher volume following its announcement of positive results from a pivotal study, ARTISAN-SNM , evaluating its implantable Axonics r-SNM neuromodulator for the treatment of urinary urgency incontinence. Mo...

AXNX - Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , disclosed today positiv...

AXNX - Axonics submits MRI data to FDA for its sacral neuromodulation system

Axonics Modulation Technologies (NASDAQ: AXNX ) has submitted complete test data to FDA for the purpose of gaining Conditional Full Body Magnetic Resonance Imaging (“MRI”) labeling approval for the Axonics r-SNM System for urinary and bowel dysfunction. More news on: A...

AXNX - Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced the sub...

Company Name:	Axonics Modulation Technologies Inc.
Stock Symbol:	AXNX
Market:	NASDAQ
Website:	axonics.com